Recommendations focus on radiation therapy and\/or adjunctive therapies for WHO grade 4 adult-type diffuse glioma<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, July 8, 2025 (HealthDay News) — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online June 25 in Practical Radiation Oncology<\/em>, updated recommendations are presented for the management of World Health Organization (WHO) grade 4 adult-type diffuse glioma, focusing on radiation therapy (RT) and\/or adjunctive therapies.<\/p>\n Debra Nana Yeboa, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues developed recommendations for multidisciplinary management of WHO grade 4 adult-type diffuse glioma, focusing on diagnosis, initial treatment, reirradiation, and health disparities.<\/p>\n The authors note that concurrent RT with temozolomide followed by adjuvant temozolomide is recommended for eligible patients following maximum safe resection, molecular and pathologic diagnosis, and prognostic stratification of grade 4 adult-type diffuse glioma; incorporation of alternating electric field therapy is conditionally recommended. Hypofractionated RT with concurrent and adjuvant temozolomide is conditionally recommended for elderly patients. Following multidisciplinary, patient-centered discussion, supportive and palliative care is conditionally recommended for frail patients. Following pathologic or advanced imaging confirmation of WHO grade 4 diffuse glioma recurrence, appropriate reirradiation techniques, with or without additional systemic therapy, can be considered and are conditionally recommended. Patients with grade 4 adult-type diffuse glioma have health disparities; to improve outcomes and increase clinical trial enrollment for underserved populations, attention to these issues is necessary.<\/p>\n “Our goal was to equip clinicians with a clear, robust framework for shared decision-making with their patients, while also highlighting areas where research is needed to move the field forward,” Yeboa said in a statement.<\/p>\n Several authors disclosed ties to the biopharmaceutical and medical technology industries.<\/p>\n